VC 02

Drug Profile

VC 02

Alternative Names: PEC-Direct; VC-02; VC-02 combination product

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BetaLogics; ViaCyte Inc
  • Developer ViaCyte Inc
  • Class Antihyperglycaemics; Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 21 Jul 2017 Phase-I clinical trials in Type-1 diabetes mellitus in Canada (SC) (NCT03162926)
  • 06 Jul 2017 Phase-I/II clinical trials in Type-1 diabetes mellitus in USA (SC) (NCT03163511)
  • 25 May 2017 ViaCyte plans a phase I trial for Type-1 diabetes mellitus in Canada (NCT03162926)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top